PL3500255T3 - Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania - Google Patents

Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania

Info

Publication number
PL3500255T3
PL3500255T3 PL17841144.3T PL17841144T PL3500255T3 PL 3500255 T3 PL3500255 T3 PL 3500255T3 PL 17841144 T PL17841144 T PL 17841144T PL 3500255 T3 PL3500255 T3 PL 3500255T3
Authority
PL
Poland
Prior art keywords
pharmaceutical
related uses
pharmaceutical compositions
compositions
pharmaceutical pharmaceutical
Prior art date
Application number
PL17841144.3T
Other languages
English (en)
Polish (pl)
Inventor
Claes Feinbaum
Franc Salamun
Sudhir PATEL
Original Assignee
Orasis Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orasis Pharmaceuticals Ltd. filed Critical Orasis Pharmaceuticals Ltd.
Publication of PL3500255T3 publication Critical patent/PL3500255T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
PL17841144.3T 2016-08-19 2017-08-18 Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania PL3500255T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377154P 2016-08-19 2016-08-19
PCT/IB2017/001140 WO2018033792A2 (en) 2016-08-19 2017-08-18 Ophthalmic pharmaceutical compositions and uses relating thereto

Publications (1)

Publication Number Publication Date
PL3500255T3 true PL3500255T3 (pl) 2023-03-13

Family

ID=60935566

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17841144.3T PL3500255T3 (pl) 2016-08-19 2017-08-18 Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania

Country Status (13)

Country Link
US (6) US9867810B1 (enExample)
EP (2) EP4190328A1 (enExample)
JP (3) JP7297308B2 (enExample)
KR (2) KR102472774B1 (enExample)
CN (2) CN116726006A (enExample)
AU (2) AU2017311636B2 (enExample)
CA (1) CA3031370A1 (enExample)
ES (1) ES2934790T3 (enExample)
IL (2) IL264664B2 (enExample)
MX (2) MX2019001877A (enExample)
PL (1) PL3500255T3 (enExample)
PT (1) PT3500255T (enExample)
WO (1) WO2018033792A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
PT3500255T (pt) 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
WO2019209955A2 (en) 2018-04-24 2019-10-31 Allergan, Inc. Presbyopia treatments
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
AU2019360953A1 (en) 2018-10-15 2021-05-13 Ocuphire Pharma, Inc. Methods and compositions for treatment of glaucoma and related conditions
JP7670945B2 (ja) * 2018-10-26 2025-05-01 オーパス・ジェネティクス・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
EP3965732A4 (en) * 2019-05-08 2023-06-14 Harrow IP, LLC PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA AND PROCESS FOR THEIR PREPARATION
JP7766680B2 (ja) * 2020-09-11 2025-11-10 イントラタス－ネバダ インコーポレイテッド 老視、遠視、乱視、低減した立体視、および低下したコントラスト感度を治療するための組成物および方法
MX394625B (es) * 2020-11-12 2025-03-24 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia
CA3205883A1 (en) * 2021-02-04 2022-08-11 Gregory I. Ostrow Ophthalmic compositions for presbyopia
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
US20230270671A1 (en) 2022-01-14 2023-08-31 Somerset Therapeutics, Llc Pharmaceutically stable pilocarpine formulations with substantially reduced buffer content and related methods
CN118679159A (zh) * 2022-01-29 2024-09-20 南京济群医药科技股份有限公司 一种m-胆碱受体激动剂化合物及其制备方法和用途
US12156868B2 (en) 2022-02-09 2024-12-03 Somerset Therapeutics, Llc Formulations of pilocarpine and brimonidine compounds and related methods

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5698533A (en) 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
TW389694B (en) 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
WO1997033562A1 (en) 1996-03-13 1997-09-18 Laboratoires Merck Sharp & Dohme-Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase transition
WO1998051281A1 (en) 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020128267A1 (en) 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US6605640B2 (en) 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20040058926A1 (en) 2001-05-04 2004-03-25 Rebanta Bandyopadhyay Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20030018382A1 (en) 2001-07-17 2003-01-23 Pflugfelder Stephen C. Process for improving vision
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2839930C (en) 2003-06-13 2016-07-05 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
DE602004023516D1 (de) * 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
KR20090053892A (ko) * 2006-07-25 2009-05-28 오스모티카 코프. 점안액
ES2329161T3 (es) 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
WO2008074865A1 (en) * 2006-12-21 2008-06-26 Novo Nordisk A/S Dimeric prolactin receptor ligands
BRPI0807065A2 (pt) 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
WO2008130591A2 (en) 2007-04-18 2008-10-30 The Gi Company, Inc. Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
CN101754748A (zh) 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2515911A4 (en) 2009-12-23 2013-08-07 Alimera Sciences Inc METHOD FOR REDUCING THE IMPACT OF INTRAOCULAR PRESSURE RELATED TO THE INTRA-OCCULAR APPLICATION OF CORTICOSTEROIDS
PH12014500636B1 (en) 2011-09-20 2019-11-20 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
US20170007637A1 (en) * 2014-02-11 2017-01-12 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
PT3500255T (pt) * 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas

Also Published As

Publication number Publication date
US20200222369A1 (en) 2020-07-16
US20180207136A1 (en) 2018-07-26
IL264664B2 (en) 2023-03-01
MX2019001877A (es) 2019-09-13
US20220184039A1 (en) 2022-06-16
US10639297B2 (en) 2020-05-05
IL264664B (en) 2022-11-01
US11129812B2 (en) 2021-09-28
CA3031370A1 (en) 2018-02-22
WO2018033792A3 (en) 2018-03-29
US20250268867A1 (en) 2025-08-28
KR20190051973A (ko) 2019-05-15
KR102588499B1 (ko) 2023-10-11
CN109803652A (zh) 2019-05-24
KR20220162876A (ko) 2022-12-08
EP3500255A2 (en) 2019-06-26
BR112019002967A2 (pt) 2019-05-14
KR102472774B1 (ko) 2022-11-30
US11974986B2 (en) 2024-05-07
RU2019107585A3 (enExample) 2020-12-22
JP7297308B2 (ja) 2023-06-26
JP2025168426A (ja) 2025-11-07
ES2934790T3 (es) 2023-02-27
EP4190328A1 (en) 2023-06-07
AU2023226732A1 (en) 2023-09-28
MX2023003124A (es) 2023-03-22
AU2017311636B2 (en) 2023-08-10
AU2017311636A1 (en) 2019-02-14
US9867810B1 (en) 2018-01-16
US20180318264A1 (en) 2018-11-08
WO2018033792A2 (en) 2018-02-22
JP2019524826A (ja) 2019-09-05
CN116726006A (zh) 2023-09-12
EP3500255A4 (en) 2020-03-25
JP2023105147A (ja) 2023-07-28
PT3500255T (pt) 2023-01-10
EP3500255B1 (en) 2022-11-30
RU2019107585A (ru) 2020-09-21
IL297367A (en) 2022-12-01
IL264664A (enExample) 2019-03-31

Similar Documents

Publication Publication Date Title
PL3500255T3 (pl) Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania
PL3607069T3 (pl) Produkty i kompozycje
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
DK3529248T3 (da) Farmaceutiske sammensætninger
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
EP3474820C0 (en) GLP-1 COMPOSITIONS AND ITS USES
EP3513809A4 (en) MEDICAL COMPOSITION
EP3497209A4 (en) CHEMERICAL POXVIRUS COMPOSITIONS AND THEIR USES
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
DK3655017T3 (da) Farmaceutisk sammensætning
EP3522882A4 (en) AMINO ACID COMPOSITIONS AND USES THEREOF
LT3426226T (lt) Oftalmologinė kompozicija
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
PL3293188T3 (pl) Silany i utwardzalne kompozycje obejmujące wskazane silany
BR112018000054A2 (pt) composições farmacêuticas liofilizadas
PT3261437T (pt) Compostos e composições fungicidas
EP3554470A4 (en) COSMETIC COMPOSITIONS
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3583943T3 (da) Farmaceutisk sammensætning
IL264445A (en) Compounds and compositions and uses thereof
DK3528791T3 (da) Dispergible sammensætninger
EP3471711A4 (en) ANTI-MALARIAL COMPOSITIONS AND THEIR USES